Rodman & Renshaw Begins Coverage on Sana Biotechnology (NASDAQ:SANA)

Investment analysts at Rodman & Renshaw began coverage on shares of Sana Biotechnology (NASDAQ:SANA) in a research note issued to investors on Monday. The brokerage set a “buy” rating and a $16.00 price target on the stock. Rodman & Renshaw’s target price would indicate a potential upside of 355.84% from the stock’s previous close.

A number of other research analysts also recently commented on SANA. Wedbush upped their price objective on Sana Biotechnology from $6.00 to $7.00 and gave the stock an “outperform” rating in a research note on Tuesday, April 14th. Zacks Research downgraded Sana Biotechnology from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, March 3rd. Wall Street Zen upgraded Sana Biotechnology from a “strong sell” rating to a “sell” rating in a research note on Saturday. Morgan Stanley restated an “overweight” rating and set a $12.00 price objective on shares of Sana Biotechnology in a research note on Friday, March 13th. Finally, Weiss Ratings lowered Sana Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, May 1st. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $9.50.

Sana Biotechnology Price Performance

Shares of SANA opened at $3.51 on Monday. The company has a market cap of $947.66 million, a P/E ratio of -3.62 and a beta of 2.17. The stock has a fifty day moving average price of $3.36 and a 200 day moving average price of $4.04. Sana Biotechnology has a 12 month low of $1.60 and a 12 month high of $6.55.

Sana Biotechnology (NASDAQ:SANA) last issued its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.03). As a group, research analysts anticipate that Sana Biotechnology will post -0.59 earnings per share for the current year.

Institutional Trading of Sana Biotechnology

Several institutional investors have recently modified their holdings of SANA. AQR Capital Management LLC lifted its holdings in shares of Sana Biotechnology by 49.8% in the first quarter. AQR Capital Management LLC now owns 573,146 shares of the company’s stock valued at $963,000 after buying an additional 190,483 shares during the period. Woodline Partners LP lifted its holdings in shares of Sana Biotechnology by 13.1% in the first quarter. Woodline Partners LP now owns 780,656 shares of the company’s stock valued at $1,312,000 after buying an additional 90,515 shares during the period. Franklin Resources Inc. lifted its holdings in shares of Sana Biotechnology by 86.8% in the second quarter. Franklin Resources Inc. now owns 93,081 shares of the company’s stock valued at $254,000 after buying an additional 43,247 shares during the period. Rhumbline Advisers lifted its holdings in shares of Sana Biotechnology by 11.6% in the second quarter. Rhumbline Advisers now owns 203,283 shares of the company’s stock valued at $555,000 after buying an additional 21,149 shares during the period. Finally, Prudential Financial Inc. acquired a new stake in shares of Sana Biotechnology in the second quarter valued at $50,000. Institutional investors and hedge funds own 88.23% of the company’s stock.

Sana Biotechnology Company Profile

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.